BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 26569487)

  • 1. Costs and Cost Effectiveness of Three Approaches for Cervical Cancer Screening among HIV-Positive Women in Johannesburg, South Africa.
    Lince-Deroche N; Phiri J; Michelow P; Smith JS; Firnhaber C
    PLoS One; 2015; 10(11):e0141969. PubMed ID: 26569487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and cost-effectiveness of LEEP versus cryotherapy for treating cervical dysplasia among HIV-positive women in Johannesburg, South Africa.
    Lince-Deroche N; van Rensburg C; Roseleur J; Sanusi B; Phiri J; Michelow P; Smith JS; Firnhaber C
    PLoS One; 2018; 13(10):e0203921. PubMed ID: 30308014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of HPV-based cervical cancer screening in the public health system in Nicaragua.
    Campos NG; Mvundura M; Jeronimo J; Holme F; Vodicka E; Kim JJ
    BMJ Open; 2017 Jun; 7(6):e015048. PubMed ID: 28619772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries.
    Mandelblatt JS; Lawrence WF; Gaffikin L; Limpahayom KK; Lumbiganon P; Warakamin S; King J; Yi B; Ringers P; Blumenthal PD
    J Natl Cancer Inst; 2002 Oct; 94(19):1469-83. PubMed ID: 12359856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of alternative strategies for primary cervical cancer screening in sub-Saharan Africa: systematic review and meta-analysis of diagnostic test accuracy studies.
    Fokom-Domgue J; Combescure C; Fokom-Defo V; Tebeu PM; Vassilakos P; Kengne AP; Petignat P
    BMJ; 2015 Jul; 351():h3084. PubMed ID: 26142020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of careHPV for detecting high-grade cervical intraepithelial neoplasia among women living with HIV-1 in Burkina Faso and South Africa: HARP study.
    Segondy M; Kelly H; Magooa MP; Djigma F; Ngou J; Gilham C; Omar T; Goumbri-Lompo O; Michelow P; Doutre S; Clavero O; Chikandiwa A; Sawadogo B; Didelot MN; Costes V; Méda N; Delany-Moretlwe S; Mayaud P
    Br J Cancer; 2016 Aug; 115(4):425-30. PubMed ID: 27434037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
    Kim JJ; Wright TC; Goldie SJ
    JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.
    Simms KT; Hall M; Smith MA; Lew JB; Hughes S; Yuill S; Hammond I; Saville M; Canfell K
    PLoS One; 2017; 12(1):e0163509. PubMed ID: 28095411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of cervical neoplasia in HIV-infected women in India.
    Joshi S; Sankaranarayanan R; Muwonge R; Kulkarni V; Somanathan T; Divate U
    AIDS; 2013 Feb; 27(4):607-15. PubMed ID: 23079814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].
    Magnani C; Gillio Tos A; De Marco L; Calvia M; Cipelletti A; Bestagini P; Pagano E; Segnan N; Ronco G
    Epidemiol Prev; 2012; 36(2):88-94. PubMed ID: 22706358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study.
    Shi JF; Canfell K; Lew JB; Zhao FH; Legood R; Ning Y; Simonella L; Ma L; Kang YJ; Zhang YZ; Smith MA; Chen JF; Feng XX; Qiao YL
    BMC Cancer; 2011 Jun; 11():239. PubMed ID: 21668946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective cohort study examining cervical cancer screening methods in HIV-positive and HIV-negative Cambodian Women: a comparison of human papilloma virus testing, visualization with acetic acid and digital colposcopy.
    Thay S; Goldstein A; Goldstein LS; Govind V; Lim K; Seang C
    BMJ Open; 2019 Feb; 9(2):e026887. PubMed ID: 30804036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget impact analysis of cervical cancer screening in Portugal: comparison of cytology and primary HPV screening strategies.
    Pista A; Costa C; Saldanha C; Moutinho JAF; Moutinho JM; Arrobas F; Catalão C; Kempers J
    BMC Public Health; 2019 Feb; 19(1):235. PubMed ID: 30808324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and costs of using HPV testing to screen for cervical cancer.
    Mandelblatt JS; Lawrence WF; Womack SM; Jacobson D; Yi B; Hwang YT; Gold K; Barter J; Shah K
    JAMA; 2002 May; 287(18):2372-81. PubMed ID: 11988058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Costs and cost-effectiveness of cervical cancer screening strategies in women living with HIV in Burkina Faso: The HPV in Africa Research Partnership (HARP) study.
    Devine A; Vahanian A; Sawadogo B; Zan S; Bocoum FY; Kelly H; Gilham C; Nagot N; Ong JJ; Legood R; Meda N; Miners A; Mayaud P;
    PLoS One; 2021; 16(3):e0248832. PubMed ID: 33765011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country.
    Vanni T; Luz PM; Grinsztejn B; Veloso VG; Foss A; Mesa-Frias M; Legood R
    Int J Cancer; 2012 Jul; 131(2):E96-104. PubMed ID: 21964797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness and health economic analysis of strategies on cervical cancer screening and early diagnosis and treatment].
    Zhao FH; Chen JF; Gao XH; Gao LM; Liu QG; Liu ZH; Xu H; Ma JF; Ma L; Xu XL; Hu SY; Ning Y; Shi JF; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):632-6. PubMed ID: 23159002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.